Impact of the patient population on the risk for heparin-induced thrombocytopenia
- PMID: 10961867
Impact of the patient population on the risk for heparin-induced thrombocytopenia
Abstract
The frequency of immune heparin-induced thrombocytopenia (HIT) varies among prospective studies. It is unknown whether this is caused by differences in the heparin preparations, the patient populations, or the types of serologic assay used to confirm the diagnosis. Seven hundred forty-four patients were studied from 3 different clinical treatment settings, as follows: unfractionated heparin (UFH) during or after cardiac surgery (n = 100), UFH after orthopedic surgery (n = 205), and low-molecular-weight heparin (LMWH) after orthopedic surgery (n = 439). Both an activation assay and an antigen assay were used to detect heparin-dependent IgG (HIT-IgG) antibodies. By activation assay, the frequency of HIT-IgG formation ranged from a low of 3.2% in orthopedic patients receiving LMWH to a high of 20% in cardiac patients receiving UFH; by antigen assay, the corresponding frequencies ranged from 7.5% to 50%. Both UFH use (P =.002) and cardiac surgery (P =.01) were more likely to be associated with HIT-IgG formation. However, among patients in whom HIT-IgG formed and who were administered UFH, the probability for HIT was higher among orthopedic patients than among cardiac patients (by activation assay: 52.6% compared with 5%; odds ratio, 21.1 [95% CI, 2.2-962.8]; P =.001; by antigen assay: 34.5% compared with 2.0%; odds ratio, 25.8 [95% CI, 3.2-1141]; P <.001). It is concluded that there is an unexpected dissociation between the frequency of HIT-IgG formation and the risk for HIT that is dependent on the patient population. HIT-IgG antibodies are more likely to form in patients who undergo cardiac surgery than in orthopedic patients, but among patients in whom antibodies do form, orthopedic patients are more likely to develop HIT. (Blood. 2000;96:1703-1708)
Similar articles
-
Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive.J Thromb Haemost. 2010 Jan;8(1):30-6. doi: 10.1111/j.1538-7836.2009.03626.x. Epub 2009 Sep 28. J Thromb Haemost. 2010. PMID: 19793190
-
Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.J Lab Clin Med. 1996 Oct;128(4):376-83. doi: 10.1016/s0022-2143(96)80009-6. J Lab Clin Med. 1996. PMID: 8833886
-
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.Thromb Res. 2002 Oct 1;108(1):49-55. doi: 10.1016/s0049-3848(02)00397-3. Thromb Res. 2002. PMID: 12586132 Clinical Trial.
-
Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.Semin Thromb Hemost. 2004 Feb;30 Suppl 1:69-80. doi: 10.1055/s-2004-823005. Semin Thromb Hemost. 2004. PMID: 15085468 Review.
-
New approaches to the diagnosis of heparin-induced thrombocytopenia.Chest. 2005 Feb;127(2 Suppl):35S-45S. doi: 10.1378/chest.127.2_suppl.35S. Chest. 2005. PMID: 15706029 Review.
Cited by
-
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.J Pediatr Pharmacol Ther. 2012 Jan;17(1):12-30. doi: 10.5863/1551-6776-17.1.12. J Pediatr Pharmacol Ther. 2012. PMID: 23118656 Free PMC article.
-
Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages.J Thromb Haemost. 2015 Aug;13(8):1416-27. doi: 10.1111/jth.13003. Epub 2015 Jul 14. J Thromb Haemost. 2015. PMID: 25960020 Free PMC article.
-
Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes.Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):294S-300S. doi: 10.1177/1076029618808915. Epub 2018 Nov 12. Clin Appl Thromb Hemost. 2018. PMID: 30419766 Free PMC article.
-
Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature.J Trauma Manag Outcomes. 2010 Jan 6;4:1. doi: 10.1186/1752-2897-4-1. J Trauma Manag Outcomes. 2010. PMID: 20205800 Free PMC article.
-
Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia.Br J Haematol. 2022 Jun;197(6):766-790. doi: 10.1111/bjh.18120. Epub 2022 Mar 31. Br J Haematol. 2022. PMID: 35358358 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical